Journal of the National Comprehensive Cancer Network · 2018 · 63 citations · 52 references
MedicineOncologyChemotherapyHematologic OncologyTreatment PlanningCancer StagingHematologic Malignancy TherapyRelapsed DiseaseSupportive Care In CancerSupportive OncologyTherapy Response AssessmentHodgkin Lymphoma TherapyHodgkin Lymphoma TreatmentLymphoma RelapseRefractory Hodgkin LymphomaRefractory Non-hodgkin LymphomaRelapse Lymphoma CareRelapsed Hodgkin LymphomaRelapsed Non-hodgkin Lymphoma
The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN Guidelines Panel meets at least annually to review comments from reviewers within the NCCN Member Institutions, examine relevant data, and reevaluate and update the recommendations. These NCCN Guidelines Insights summarize recent updates centered on treatment considerations for relapsed/refractory classic HL.
52
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Norbert Schmitz, Beate Pfistner, M. Sextro et al. · The Lancet · 2002 · 1.1K citations